updated chart, page-2834

Its conceivable that we could get updates on any of the following:-

• Further pre-clincal OmniCAR optimisation data

• Interim readout of PTX-200 given that its been 6 mths since the last one

• MD Anderson Collaboration

The latter one is based on a bit of "hopium" of mine that whilst we will be incorporating their TCR binder in our OmniCAR trial for AML next year, its possible that MDA might be keen to incorporate OmniCAR in one of their upcoming CarT trials. We know they conduct a lot of trials themselves at their own in-house facilities.

And, right out on a limb of tiny expectation is a partnership or any number of partnerships from all the conference exposure (recent and not-so-recent) and supposed "full dance card" that SYC references. OmniCAR and CellPryme-A could land a clinical trial partner... and CellPryme-M could land a partner/s planning clinical trials. There's also the potential for partner/s with commercialised therapies that could present as customers of CP-M. Cell manufacturers such as Q-Gen could even present as a parter for CP-M. But these possibilites are of a much bigger milestone that may require much more patience and realistic expectation than some can muster.